Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
At present 18 per cent of the local pharmaceutical market is under government's price control
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
The trial will be conducted across 10 sites in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Subscribe To Our Newsletter & Stay Updated